

## Special Issue

# Epidemiology and Real-World Evidence to Inform Vaccine Design, De-Risk Development, and Maximize Real-World Impact

### Message from the Guest Editors

Epidemiological insights are critical for defining areas for improvement in public health, understanding transmission dynamics, and identifying high-risk or high-impact populations—all of which directly inform target product profiles, development priorities, and the design of clinical trials. Real-world evidence (RWE) further strengthens the value of vaccine candidates by contextualizing clinical trial data, supporting regulatory submissions, and demonstrating effectiveness and safety in real-world use. RWE is also a key tool for detecting rare safety signals, tracking the impact of variants, and quantifying broader effects, such as herd protection. Collectively, epidemiology and RWE enable more strategic decision-making, reduce development risk, and improve the likelihood of successful product adoption and the likelihood that vaccines will exert a sustained impact.

This Special Issue welcomes contributions that demonstrate how epidemiology and RWE can be effectively leveraged to inform vaccine design, de-risk development, accelerate timelines, and optimize real-world implementation.

---

### Guest Editors

Dr. Hilary Whitworth

IAVI Africa, Black River Park, Observatory, Cape Town 7925, South Africa

Dr. Suzanna C. Francis

IAVI Europe, Van Diemenstraat 48, 1013 NJ Amsterdam, The Netherlands

---

### Deadline for manuscript submissions

30 June 2026



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/247648](https://mdpi.com/si/247648)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).